DELL vs PFE: Which Is the Better Buy?
Side-by-side comparison of Dell Technologies Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-21.
Dell Technologies Inc. · Technology
$569.00
-32.5% upside to fair value
Low Conviction
Grade C
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+12.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DELL |
PFE |
| Current Price |
$569.00 |
$27.64 |
| Fair Value Estimate |
$383.93 |
$30.94 |
| Upside to Fair Value |
-32.5%
|
+12.0%
|
| Market Cap |
$378.0B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
21.8x
|
17.4x
|
| Price / Sales |
2.5x
|
2.5x
|
| Price / FCF |
42.9x
|
14.3x
|
| Revenue Growth YoY |
+57.7%
|
+2.6%
|
| Gross Margin |
19.8%
|
71.3%
|
| Operating Margin |
9.6%
|
25.1%
|
| Return on Equity |
-574.6%
|
4.9%
|
| Dividend Yield |
0.41% |
6.22% |
| FCF Yield |
2.33%
|
6.97%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
Dell Technologies is a $378 billion market-cap computer hardware vendor spanning Infrastructure Solutions Group (servers, storage, networking), Client Solutions Group (PCs, displays, peripherals), and a VMware-related software franchise, led by founder-CEO Michael Dell. The business is fundamentally low-quality on the numbers: TTM gross margin is 19.8%, operating margin 9.6%, and net margin 7.5%,…
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
DELL |
PFE |
| Zone Low |
$287.95 |
$23.21 |
| Zone High |
$326.34 |
$26.30 |
| In Buy Zone? |
No
|
No
|